FDA Places Andrx's ANDAs on Hold in Wake of cGMP Observations

Drug Industry Daily
KEYWORDS ANDA / FDA / Warning
A A

The FDA’s Florida District office has placed Andrx’s pending abbreviated new drug applications (ANDAs) on hold due to manufacturing problems — a move that could potentially threaten the generic firm’s portfolio of previously approved drugs.

To View This Article:

Login

Subscribe To Drug Industry Daily